Orelabrutinib

Generic Name
Orelabrutinib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C26H25N3O3
CAS Number
1655504-04-3
Unique Ingredient Identifier
WJA5UO9E10
Background

Orelabrutinib is under investigation in clinical trial NCT04305197 (A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)).

Indication

⑴既往至少接受过一种治疗的成人套细胞淋巴瘤(MCL)患者。

⑵既往至少接受过一种治疗的成人慢性淋巴细胞白血病(CLL)/小淋巴细胞淋巴瘤(SLL)患者。

Associated Conditions
-
Associated Therapies
-

A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP

First Posted Date
2021-08-25
Last Posted Date
2021-08-25
Lead Sponsor
Shandong University
Target Recruit Count
40
Registration Number
NCT05020288

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

First Posted Date
2021-08-04
Last Posted Date
2022-03-24
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
32
Registration Number
NCT04989621
Locations
🇨🇳

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,, Guangzhou, Guangdong, China

🇨🇳

Guangdong General Hospital, Guangzhou, Guangdong, China

🇨🇳

Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,, Guangzhou, Guangdong, China

Orelabrutinib and Sintilimab in Relapsed or Refractory Central Nervous System Lymphoma

First Posted Date
2021-07-14
Last Posted Date
2022-11-08
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
48
Registration Number
NCT04961515
Locations
🇨🇳

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma

First Posted Date
2021-05-24
Last Posted Date
2021-05-24
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
32
Registration Number
NCT04899427
Locations
🇨🇳

Wei Zhang, Beijing, Beijing, China

A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2021-01-15
Last Posted Date
2023-04-21
Lead Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Target Recruit Count
160
Registration Number
NCT04711148
Locations
🇨🇳

The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, China

🇺🇸

Neurology Associates, P.C., Lincoln, Nebraska, United States

🇺🇦

CNE Regional Clinical Hospital of Ivano-Frankivsk Regional Council, Ivano-Frankivsk, Ukraine

and more 39 locations

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

First Posted Date
2020-03-11
Last Posted Date
2024-02-07
Lead Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Target Recruit Count
43
Registration Number
NCT04304040
Locations
🇨🇳

The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China

🇨🇳

Beijing Hospital, Beijing, Beijing, China

🇨🇳

Affiliated Hospital of Hebei University, Baoding, Hebei, China

and more 7 locations
© Copyright 2024. All Rights Reserved by MedPath